Conatus Pharmaceutic (CNAT) 2.02 $CNAT Conatus (CNAT)

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 10:13 AM

Conatus Pharmaceutic (CNAT) 2.02 $CNAT

Conatus (CNAT) Posts In Line Q1 Loss , Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:32AM CDT
Conatus Pharmaceuticals (CNAT) reported first-quarter 2016 loss of 35 cents per share, in line with the Zacks Consensus Estimate.
VTL: 7.59 (-0.23), ANIP: 52.05 (-1.64), CNAT: 2.02 (-0.11), RTRX: 17.40 (-0.30)

Conatus' (CNAT) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Thu May 05, 8:30AM CDT
Conatus' first-quarter 2016 loss of 35 cents per share came in line with consensus estimates.
CNAT: 2.02 (-0.11)

Conatus reports 1Q loss
Automated Insights - Thu May 05, 6:40AM CDT
SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $7.3 million in its first quarter.
CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Reports First Quarter 2016 Financial Results and Program Updates
GlobeNewswire - Thu May 05, 6:00AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results for the first quarter ended March 31, 2016, and provided updates on its development programs. After the market close yesterday, the company announced top-line results from the second stage of its Phase 2 Liver Cirrhosis trial. A conference call and webcast are scheduled for 8:00 a.m. ET today, as detailed below, to discuss both the trial results and financial results.
CNAT: 2.02 (-0.11)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)

Conatus (CNAT): Can the Stock Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:57PM CDT
Conatus (CNAT) is scheduled to report first-quarter 2016 results on May 5, before market opens.
ZTS: 47.39 (-0.75), IPXL: 32.45 (-1.11), CNAT: 2.02 (-0.11), JAZZ: 150.76 (-5.26)

Conatus Pharmaceuticals to Report First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 28, 6:32AM CDT
Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the first quarter ended March 31, 2016, before the market opens on Thursday, May 5, 2016. Conatus will host a conference call and audio webcast at 8:00 a.m. Eastern Time on Thursday, May 5, 2016, to discuss the financial results and provide a corporate update.
CNAT: 2.02 (-0.11)

Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
GlobeNewswire - Mon Apr 18, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced today the delivery of a late breaker oral presentation at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016. The presentation (#LBO5) entitled, "Emricasan (IDN-6556) orally for three months in patients with cirrhosis and MELD scores 11-18 improves clinical parameters of cirrhosis in patients with baseline MELD score greater-than or equal to15," was delivered on Saturday, April 16, at 5:00 p.m. CET, by Catherine Frenette, M.D., Medical Director of Liver Transplantation at Scripps Clinic, La Jolla, CA, and a principal investigator in the company's multicenter Phase 2 Liver Cirrhosis clinical trial of emricasan. The presentation visuals are available in the Clinical Data section of the Conatus website at www.conatuspharma.com.
CNAT: 2.02 (-0.11)

Conatus Poster at EASL Meeting Today Addresses Safety of Caspase Inhibition in Cancer Treatment
GlobeNewswire - Fri Apr 15, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that a poster addressing results in both ex vivo cell culture and in vivo mouse models of hepatocellular carcinoma with IDN-7314, an orally active pan-caspase inhibitor, is being presented today at The International Liver Congress(TM) 2016, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Barcelona, Spain, April 13-17, 2016.
CNAT: 2.02 (-0.11)

Penny Stocks: Wednesday's List Of Trending Micro Cap And Small Cap Equities
ACCESSWIRE - Wed Apr 06, 11:25AM CDT
MIAMI, FL / ACCESSWIRE / April 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TRTC, NETE, SFOR, and UNXL have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
VCRA: 12.46 (-0.04), CNAT: 2.02 (-0.11)

Conatus to Present at Needham Healthcare Conference
GlobeNewswire - Tue Apr 05, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced its scheduled presentation to provide an overview of the company's programs and outlook at the 15 Annual Needham Healthcare Conference on Wednesday, April 13, 2016, at 9:20 a.m. ET, in New York. An audio webcast and copy of the presentation will be available in the Investors section of the company's website at www.conatuspharma.com.
CNAT: 2.02 (-0.11)

Penny Stocks To Buy: Traders Are Considering Stocks On This List, Monday 4/4/2016
ACCESSWIRE - Mon Apr 04, 10:43AM CDT
MIAMI, FL / ACCESSWIRE / April 4, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. ZFGN, CNAT, CRC, and TRTC have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
ZFGN: 6.39 (-0.20), CRC: 14.12 (-3.36), CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Appoints Edward F. Smith III as Senior Vice President, Regulatory Affairs and Quality Assurance
GlobeNewswire - Mon Apr 04, 6:30AM CDT
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the appointment of Edward F. Smith III, Ph.D., as Senior Vice President, Regulatory Affairs and Quality Assurance.
CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Announces Acceptance of Abstracts for EASL Meeting
GlobeNewswire - Wed Mar 30, 6:30AM CDT
- Late Breaker Oral Presentation of Phase 2 Liver Cirrhosis Trial Three-month Data -
CNAT: 2.02 (-0.11)

Conatus' Loss Narrower than Expected, Focus on Emricasan
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 8:00AM CST
Conatus Pharmaceuticals (CNAT) reported narrower-than-expected fourth-quarter 2015 loss of 30 cents per share.
CNAT: 2.02 (-0.11), BXLT: 46.02 (-0.18), ANIK: 49.16 (+0.24)

Can Conatus (CNAT) Surprise Estimates in Q4 Earnings?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 9:10AM CST
Conatus Pharmaceuticals (CNAT), which is scheduled to report fourth-quarter 2015 results on Mar 9, delivered a positive earnings surprise of 13.89% last quarter.
BDSI: 2.67 (-0.18), ALNY: 63.17 (-2.24), GILD: 84.45 (-1.32), CNAT: 2.02 (-0.11)

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) FDA has Granted Fast Track Designation for Emricasan Analyst Comments
ACCESSWIRE - Tue Feb 09, 8:06AM CST
SAN DIEGO, CA / ACCESSWIRE / February 9, 2016 / Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) a biotechnology company focused on the development and commercialization of medicines to treat liver disease, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). Based on additional communications with the FDA recommending single-etiology clinical trials, the company plans to focus on advancing toward initial registration of emricasan for patients with NASH cirrhosis, with parallel development toward registration of emricasan for patients with NASH fibrosis, and supportive clinical trials addressing additional patient populations. The Fast Track program provides for greater access to FDA to facilitate development and expedite review of drugs that have demonstrated the potential to treat serious or life-threatening conditions.
CNAT: 2.02 (-0.11)

Conatus Up on Fast Track Status for Emricasan in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Feb 04, 1:40PM CST
Shares of Conatus Pharmaceuticals Inc. (CNAT) soared 22.5% after the company announced that the FDA has granted Fast Track designation to the company's lead pipeline candidate, emricasan,
CNAT: 2.02 (-0.11), CORT: 5.60 (+0.13), PCRX: 44.07 (-1.34), BIOD: 0.34 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MIT Study: Reinforced Masonry Slashes Hurricane Damage

Building Smarter: Concrete vs. The Storm Hurricanes are nature’s wrecking balls, and if there’s one thing the latest MIT study tosses on the table, it’s that reinforced concrete masonry isn't just holding its ground—it's changing the game. You see, when Hurricane Irma swung through Florida, it left a clear message written in the rubble: smarter building means...

Coastal Construction Revamps South Florida's Equipment Game

Revolutionizing Equipment Acquisition in South Florida Looks like the sun's shining a bit differently on South Florida's contractors. Coastal Construction Equipment, LLC just announced their big debut as a new player on the Cat Compact™ scene, turning the tides for those in the construction industry. With a plan that's as big as a bulldozer, they'll be breaking ground,...

Navigating Car Wreck Chaos for Legal Protection

Clarity Amid Chaos: Handling a Crash in Abilene Let me tell you, if your day starts with a car wreck, every second post-crash counts more than you think. Attorney Chaile Allen out of Abilene's laying down the law on how to protect yourself—because that wreck scene ain't just about bent fenders and bruised egos. It's about getting your ducks in a row for any potential...

TransDigm Surges Ahead with Strong Q4 and FY Results

TransDigm's Impressive Performance in Fiscal 2026 Here's a company that's really kicking it up a notch—TransDigm Group (NYSE:TDG) just reported some solid fourth-quarter numbers that scream growth. Net sales soared to $2,988 million, marking a 23% hike from last year's fourth quarter of $2,437 million. That's a cool $551 million leap, quite the party for shareholders....

Wijmo's Accessibility Update: A Step Forward in Inclusion

A Giant Leap for Web Accessibility Web accessibility is no longer just a box-checking exercise; it's a movement towards leveling the playing field for all users. Now, with Wijmo hitting WCAG 2.2 Level AA compliance, we've got something worth noticing—a pivotal moment for inclusive design in tech. This ain't just your typical software update; it's a game-changer, making...

Phoenix's 51st Half Marathon Marks a New Era

Life Time's New Chapter in Phoenix Walking through Biltmore Fashion Park this past Sunday, the energy was palpable. Nearly 4,000 runners, hailing from 37 states and eight countries, gathered to tackle the 51st annual Life Time Phoenix Half Marathon and 10K. It was a sight, marking a fresh chapter as Life Time (NYSE: LTH) took the reins. If you’re mouthing “Life...

NHTSA, Ad Council Unveil New Anti-Buzzed Driving PSAs

Taking Aim at a Deadly Habit Everyone's got that gut feeling when a day-long meeting runs over or you're stuck in traffic — impatience morphed with slow burn menace. Now picture a whole campaign gunning for that vibe but in the hands of the young folks, those from 21 to 34. That's what we're talking about here, with the Ad Council and NHTSA serving up some fresh public...

Greenberg Traurig Shareholders Earn Law360 MVP Honors

A Spotlight on Legal Excellence In the tough-as-nails world of legal battles, a select few rise above the rest, but it's not every day you see three folks from the same shop getting the nod as MVPs. That's the story coming out of Greenberg Traurig, where shareholders Gregory A. Fishman, Michael J. Thomas, and David B. Weinstein made the cut for the 2026 Law360 MVP honors....

Lindian Secures Key Offtake for Rare Earths Expansion

Lindian Resources Drives New Deal in Rare Earths Ah, the sweet smell of another strategic move in the resources game. Lindian Resources Limited is strutting its stuff down under by securing a binding offtake for a hefty 30,000 tonnes of Monazite Concentrate. Now, that's a weighty lift in the world of rare earths, and it kicks off just in time for their December production...

Rising Tide: Luxury Cruises Attract Broader Audience

The Lure of the High Seas Who knew luxury cruises would ever shed their elitist skin and become every man's (and woman's) dream? That's what the latest survey from Cruiseline.com and Shipmate is scribbling across the page. Once a playground for the glitzy crowd, luxury cruising now appeals to a broader swath of travelers. They’ve tossed tradition overboard and are...